Notwithstanding encouraging clinical data, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant difficulty from pharmacy benefit managers. These organizations are typically erecting limitations to access, including significant expense criteria and approval processes that limit p… Read More